TWYNSTA Drug Patent Profile

When do Twynsta patents expire, and what generic alternatives are available?

Twynsta is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in TWYNSTA is amlodipine besylate; telmisartan. There are fifty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amlodipine besylate; telmisartan profile page.

Summary for TWYNSTA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TWYNSTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	TWYNSTA	amlodipine besylate; telmisartan	TABLET;ORAL	022401-001	Oct 16, 2009		DISCN	Yes	No
Boehringer Ingelheim	TWYNSTA	amlodipine besylate; telmisartan	TABLET;ORAL	022401-004	Oct 16, 2009		DISCN	Yes	No
Boehringer Ingelheim	TWYNSTA	amlodipine besylate; telmisartan	TABLET;ORAL	022401-003	Oct 16, 2009		DISCN	Yes	No
Boehringer Ingelheim	TWYNSTA	amlodipine besylate; telmisartan	TABLET;ORAL	022401-002	Oct 16, 2009		DISCN	Yes	No

International Patents for TWYNSTA

See the table below for patents covering TWYNSTA around the world.

Country	Patent Number	Title	Estimated Expiration
Slovakia	394492	BENZIMIDAZOLES, PROCESS FOR THEIR PREPARATION AND DRUG CONTAINING THE SAME
Mexico	9302034	BENCIDAZOLES, MEDICAMENTOS QUE CONTIENEN ESTOS COMPUESTOS Y PROCEDIMIENTOS PARA SU PREPARACION.
Brazil	1100667
Luxembourg	91802

Supplementary Protection Certificates for TWYNSTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0502314	1190006-5.L	Sweden		PRODUCT NAME: TELMISARTAN, VALFRITT I FORM AV FARMACEUTISKT GODTAGBARA SALT, OCH AMLODIPIN, VALFRITT I FORM AV FARMACEUTISKT GODTAGBARA SALT SAERSKILT AMOLODIPINBESILAT; REG. NO/DATE: EU/1/10/648/001-028 " EESGODKLANDKOD="EG" EESGODKDATUM="2010-10-07" SEGODKNR="EU/1/10/648/001-028 " SEGODKLANDKOD="EG" SEGODKDATUM="2010-10-07" FLAG="L" SPCNR="1190006-5" 20101007
1915993	C300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0502314	C00502314/03	Switzerland		PRODUCT NAME: TELMISARTAN + AMLODIPIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 61270 08.11.2010
1507558	2012/018	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705

TWYNSTA Market Analysis and Financial Projection

Last updated: February 3, 2026

What is TWYNSTA and its current market status?

TWYNSTA (telmisartan and amlodipine) is a fixed-dose combination (FDC) antihypertensive drug marketed by Boehringer Ingelheim. It combines telmisartan, an angiotensin II receptor blocker (ARB), with amlodipine, a calcium channel blocker (CCB). The drug aims to reduce blood pressure and lower cardiovascular risk.

The compound is approved in multiple markets, including the United States, European Union, and Japan, with regulatory approvals varying by region. Its primary indication remains for hypertension and hypertensive urgency.

What are the key market fundamentals for TWYNSTA?

Market Size and Growth

The global antihypertensive drugs market was valued at approximately USD 18 billion in 2022, with a compound annual growth rate (CAGR) of around 2.8% projected through 2029, driven by increasing hypertension prevalence and aging populations. Fixed-dose combinations constitute approximately 25% of prescribed antihypertensives, reflecting a trend towards combination therapies for better adherence.

Competitive Landscape

The FDC antihypertensive market includes drugs such as:

Product	Composition	Market Status
Twynsta	Telmisartan + Amlodipine	Approved globally
Olmetec Plus	Olmesartan + Amlodipine	Approved in Europe, marketed in the U.S.
Exforge	Amlodipine + Valsartan	Widely marketed, branded generics available

Twynsta faces competition from both branded and generic formulations. Since patent exclusivity has ended for some components, generics could impact market share, especially in lower-income regions.

Regulatory & Patent Status

• The original patent for Twynsta's composition expired around 2020 in major markets.
• Boehringer Ingelheim holds data exclusivity rights and may have additional patent protection on specific formulations or combination methods until at least 2025.
• Generics are expected to enter after patent expiry, pressuring pricing and margins.

Pricing and Reimbursement

Pricing varies by region:

• U.S.: Market average wholesale price (AWP) for branded fixed-dose combinations ranges between USD 4-8 per daily dose.
• Europe: Reimbursement policies favor generics, leading to lower prices for branded drugs.
• Japan: Pricing is regulated and typically lower, with strict reimbursement controls.

Prescriber and Patient Adoption Trends

The shift towards fixed-dose combinations reduces pill burden and improves adherence. Clinical guidelines, such as the European Society of Cardiology (ESC), endorse combination therapies early in treatment, supporting long-term demand.

What are the growth opportunities and risks?

Opportunities

• Expansion into emerging markets with rising hypertension prevalence.
• Development of next-generation formulations with improved tolerability.
• Potential for broader cardiovascular risk reduction indications.
• Increasing adoption of fixed-dose combinations in primary care settings.

Risks

• Patent expiry leading to generic competition.
• Pricing pressures from payers and regulators.
• Regulatory delays or unfavorable policy changes.
• Market saturation in mature regions.

How do clinical and regulatory trends influence investment?

Clinical guidelines increasingly favor combination therapy, which supports demand. However, patent expiry and the entry of generics threaten profit margins. Regulatory periods of data exclusivity and patent filings can extend commercial viability, but strategic investment must weigh potential declines post-patent cliff.

What are the implications for R&D and licensing?

Boehringer Ingelheim continues to pursue additional formulations and combinations, possibly including other antihypertensive agents or cardiovascular drugs. Licensing agreements for biosimilar or generic versions may offer revenue streams post-patent expiry but also increase market competition.

Closing Summary

TWYNSTA remains a noteworthy product within the antihypertensive market, benefiting from the trend toward fixed-dose combinations and guideline support. Market expansion into emerging regions and ongoing R&D are crucial for sustained growth. However, patent expiration in key markets will likely pit profitability against the tide of generic competition, requiring strategic planning for lifecycle extension.

Key Takeaways

• The global antihypertensive market is increasing modestly, supported by demographic trends.
• Fixed-dose combinations like TWYNSTA benefit from adherence improvements but face patent expiry risks.
• Competition from generics is intensifying, particularly after patent expiration.
• Regional pricing and reimbursement policies significantly affect revenues.
• R&D focus remains on new formulations and combination therapies to maintain market share.

FAQs

1. How long will TWYNSTA maintain patent exclusivity?
Patent protections for the active components have expired in major territories, likely ending around 2025, though formulation-specific patents may prolong exclusivity.

2. What are the primary competitive advantages of TWYNSTA?
Its fixed-dose combination simplifies therapy, improving patient adherence and aligning with clinical guidelines that favor early combination therapy.

3. How significant is the impact of generics on TWYNSTA's future revenues?
Once patent protections expire, generic versions are expected to reduce prices and market share, significantly impacting revenue unless the company develops new formulations or indications.

4. Can TWYNSTA expand into other cardiovascular indications?
Possible development includes expanding into heart failure or prevention of stroke; however, current approval is limited to hypertension.

5. What strategic moves can Boehringer Ingelheim pursue to sustain growth?
Investing in next-generation combination therapies, entering emerging markets, and securing licensing agreements for new uses can extend product lifecycle and revenue.

---

Sources:

[1] Industry Reports, Market Research Future, 2022
[2] European Society of Cardiology Guidelines, 2021
[3] Company filings, Boehringer Ingelheim, 2022
[4] FDA Drug Database, 2022
[5] IQVIA, 2022